By Donna Loyle, communications manager, LIMR
In this randomized phase II clinical trial, researchers are studying how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in a patient cohort comprised of African American women diagnosed with stages I-III breast cancer.
Eligible participants must have had no prior taxane therapy and no prior or concurrent platinum-based chemotherapy. Also, they must have no pre-existing neuropathy.
Participants are grouped into two study arms:
- Arm 1 receives paclitaxel IV once weekly. Treatment repeats every 21 days for 4 cycles.
- Arm 2 receives docetaxel IV once every 3 weeks. Treatment repeats every 21 days.
Patients may also receive other medications at the physician’s discretion.
Study #EAZ171 is approved for all four MLH acute care hospitals. For more, email email@example.com or visit https://www.mainlinehealth.org/research/clinical-trials/eaz171